JMJD3 overexpression in AML cells is associated with a poor prognosis, and JMJD3 inhibition facilitates an increase in H3K27 methylation associated with a decrease in proliferation and HOX expression in vitro, as well as a decrease in disease progression in vivo. The gene discussed is KDM6B; the disease is acute myeloid leukemia.